Poly (ADP-ribose) polymerase-1 (PARP-1)-deficient mice are protected against septic shock, type I diabetes, stroke and inflammation. It is now accepted that inflammation and related events, such as activation of NF-jB, are key components in the initiation and progression of epithelial cancer and in particular in the neoplastic transformation of keratinocytes and skin carcinogenesis. Here, we report that PARP-1-deficient mice display a strikingly reduced susceptibility to skin carcinogenesis. In parp-1 À/À mice, development of papilloma-like premalignant lesions induced with DMBA and TPA, is strongly delayed and the final number of tumorbearing mice and total tumor number were significantly reduced. In addition, epidermis of parp-1 À/À mice did not show increased proliferation rates after treatment with carcinogen. Deregulated NF-jB is a hallmark for tumorigenesis together with the concomitant release of early inflammatory mediators. In the absence of PARP-1, NF-jB activation and induction jB-target genes did not take place during the promotion of tumor development. These results suggest that PARP-1 abolition impairs the promotion of skin carcinogenesis interfering with the activation of NF-jB and might have an important implication in targeting PARP-1 as a new antineoplastic therapeutic approach.
Introduction
Nuclear factor-kB (NF-kB)/Rel transcription factors play a central role in the regulation of genes involved in a variety of cellular processes (Bauerle and Baltimore, 1996) . They are crucial mediators of immune and stress responses, exert pro-and antiapoptotic effects and are important in cell proliferation and differentiation. Dysregulation of the NF-kB system is thought to be involved in acute and chronic inflammatory processes as well as in cancer (Baldwin, 2001 ). The active NF-kB complex is either a homo or heterodimer composed of proteins of the NF-kB/Rel family: p50, p52, p65, Rel B and c-Rel (Israel, 2000; Li and Verma, 2002) . These structurally related interacting proteins bind as a dimer to kB motif sequences found in the promoter regions of the genes. The primary level of control for NF-kB is mediated through the cytoplasmic inhibitory proteins called IkB. When nuclear localization sequences of NFkB/Rel are covered by IkB, they are retained in the cytoplasm and do not function as active transcription factors. Most of the pathways that result in NFkB activation converge on activating the IkB kinase (IKK) complex. Upon stimulation, the IkB proteins are phosphorylated by IKK and rapidly degraded through ubiquitin-dependent proteolysis releasing NF-kB to translocate to the nucleus and to activate the expression of target genes. Several lines of evidences suggest that proteins from NF-kB and IkB families are involved in carcinogenesis. NF-kB controls the expression of several growth factors, oncogenes and tumor-suppresor genes, genes encoding cell adhesion proteins, and proteases of the extracellular matrix. Thus, dysregulation NF-kB may play a critical role in carcinogenesis through either the alteration of cell growth or disruption of cell adhesion due to gene expression patterns involved in tumor growth, invasion and metastasis (Pahl, 1999; Baldwin, 2001) . A constitutive NF-kB activation has been detected in hematopoietic malignancies such as Hodgkin's disease or acute lymphoblastic leukemia, as well as in several types of solid tumors (Bargou et al, 1996; Mayo and Baldwin, 2000) . The genes for the NFkB subunits, as well as the IkB proteins including Bcl-3 are all located at sites of recurrent translocation and genomic rearrangement in human cancer (Rayet and Gelinas, 1999) . Furthermore, a marked homology of the amino termini of both p50 and p65 with the viral oncoprotein v-Rel was found (Mayo and Baldwin, 2000) . These findings point to an involvement of NF-kB transcription factors in the initiation, development and/or promotion of carcinomas of the skin.
There is a large body of evidences involving NF-kB factors is involved in keratinocyte transformation and skin carcinogenesis. Using a murine model, the SEN-CAR mouse, the carcinogenesis of the skin has been well studied (Slaga et al., 1995) . Epidermal inflammation and hyperplasia play a critical role in skin tumor promotion and NF-kB is one of the well-known mediators of these effects (Budunova et al., 1999) . Substances like phorbol ester and okadaic acid which are promoters of skin cancer are also strong inducers of an NF-kB response in keratinocytes (Budunova et al., 1999) . Furthermore, a Ha-ras oncogene point mutation is found in over 90% of mouse skin tumors which is also implicated in NF-kB activation (Budunova et al., 1999) . Using this mouse model, it has been shown that while in normal epidermis NF-kB was expressed in the cytoplasm of basal cells, p50 and p52 are elevated in squamous cell carcinoma as well as in skin papillomas (Pandolfi et al., 1992) . IkBa protein levels are reduced in carcinoma and papilloma cells. Thus, these data are in line with other results on overexpression of p50 and p52 in solid tumors and others (Siebenlist et al., 1994; Bargou et al., 1996; Mayo and Baldwin, 2000) . Nonetheless, this concept has been challenged by the Khavari's group in a recent publication where they find that blockade of NF-kB by IkBa circumvents restraints on human epidermal cells growth promotion induced by oncogenic Ras (Dajee et al., 2003) .
On the other hand, poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear, zinc-finger, DNA-binding protein that detects specifically DNA-strand breaks generated by different genotoxic agents (de Murcia and Menissier de Murcia, 1994; D'Amours et al., 1999) . PARP-1 is associated in vivo with XRCC1, a DNA repair protein involved, together with DNA polymerase b and DNA ligase III, in the base excision repair (Masson et al., 1998) of DNA. Treatment of PARP-1 knockout mice with either alkylating agents or girradiation reveals an extreme sensitivity and a high genomic instability to both agents (de Murcia et al., 1997; Samper et al., 2001) .
In a recent study (Conde et al., 2001) , we have established that the absence of PARP-1 is able to slow down tumor formation and to increase the lifespan of p53-deficient mice by a mechanism dependent on the inhibition of oxidative stress and partial restoration of the G1/S checkpoint after DNA damage. We and others have shown that PARP-1 is a transcriptional coactivator of NF-kB and PARP-1 knockout mice are much less sensitive to inflammatory stress (Hassa and Hottiger, 1999; Oliver et al., 1999; Hassa et al., 2001) as a result of a diminished release of proinflammatory mediators, including NO. The understanding of the role and involvement of PARP-1 in many biological mechanisms, health and diseases, has steadily increased in recent years, but its role in carcinogenesis has not been completely clarified. Our results clearly support the idea that PARP-1 is an important regulator of skin carcinogenesis and this is due, at least in part, to its ability to modulate the response through NF-kB.
Results
As a first approach to elucidate the role of the interaction between PARP-1 and NF-kB in carcinogenesis, we studied the development of papilloma in PARP-1 knockout mice by the standard DMBA (7,12-dimethylbenz[a]-anthracene) plus TPA (12-Otetra-decanoyl-phorbol-13-acetate) skin carcinogenesis protocol.
Mice of a C57BL/6 background were subjected to a single topical application of carcinogen (25 mg DMBA in 100 ml of acetone) and 1 week later, to promotion with 12 mg TPA in 200 ml of acetone. Papillomas were first found in the wild-type mice 8 weeks after promotion while parp-1 À/À mice developed tumors starting at week 12, 3 weeks later than in parp-1 þ / þ mice. Tumor multiplicity, found after papillomas promotion, is similar to previously reported data for this genetic background (Moore et al., 1999) . The percentage of tumor-bearing mice at the end of treatment was 58.3% Figure 1a ). Figure 1b represents the number of tumor per mice. The papilloma latent period (number of weeks to obtain at least one papilloma per mice) for parp-1 þ / þ was 11.5 weeks while parp-1 À/À mice did not attain one tumor per mice in average during the experimental period, suggesting that the time of tumor latency in parp-1 À/À mice is largely delayed with respect to the wild-type parp-1 þ / þ strain. The differences in the number of tumor per mice obtained during the 25 weeks were statistically significant between these two groups of mice (Po0.05). Figure 1c shows the difference in morphology between papilloma in parp-1 þ / þ and parp-1 À/À taken at week 17th.
The epithelium in control mice are compound by two or three layers of cells with very thin granulosum stratum in some cases absent, and scant corneum stratum, and an homogeneous thickness of a maximum of 0.02 mm. All mice treated with DMBA plus TPA, developed epithelial hyperplasia with significant increase and irregular thickness of epithelium and granulosum stratum versus nontreated mice (Po0.0001). This treatment also induce moderate hyperkeratosis (100%), thickness of hair infundibulum (100%), and dermal pigmentary incontinence in more than 75% of parp-1 þ / þ or parp-1 À/À mice (not shown). The presence of acute inflammatory infiltrate and the number of mastocytes per mm 2 in papilloma are significantly decreased in parp-1 À/À mice versus parental mice (Figure 2a and b; Po0.01). The cell turnover is also clearly increased in parp-1 þ / þ mice versus parp-1 À/À , displaying increased mitosis (7.10/hpf) and apoptotic bodies (6.37/hpf) (Po0.05) (Figure 2a, c) .
To further support the previous observations, proliferation of keratinocytes was determined by BrdU
Interaction between PARP-1 and NF-jB in carcinogenesis D Martín-Oliva et al incorporation after 1 week challenge with DMBA and TPA as described in Materials and methods. Clearly, keratinocytes proliferation was decreased in parp-1 knockout mice compared with that in wild type. In the wild-type skin, 17.21% of basal keratinocytes labeled with BrdU compared with 9.08% in the skin from parp-1 knockout mice (Po0.01, Figure 3a , b). We have also measured apoptosis using the TUNEL assay, but this phenomenon was extraordinarily rare in the treated dorsal skin. Nonetheless, TUNEL-positive cells were more represented in wild-type tissue (Figure 3c ), suggesting that the increased rate of cell proliferation correlates with an augmented cell elimination. Mice deficient in PARP-1 display a decreased activation of the transcription factor NF-kB (Oliver et al., 1999; Hassa and Hottiger, 2002) . In order to find a mechanistic explanation for the reduced and delayed papilloma formation and the decreased keratinocytes proliferation in parp-1-deficient mice during the chemical carcinogenesis, we have focused on the activation of NF-kB and the activation of some key NF-kB responsive genes. In nuclear extracts from the epidermis of wild-type mice, TPA markedly induced NF-kB activation. However, in the skin of parp-1 À/À mice there was no activation of NF-kB during carcinogenesis (Figure 4a ). The lack of NF-kB activation is also revealed by the decreased or even absent induction of genes under the control of NF-kB such as IL-1b, MnSOD and TRAIL ligand, in the skin of parp-1 À/À mice ( Figure 4b ). TNF-a is upregulated very early after the initial TPA treatment, and we think that the lack of stimulation in TNF-a in our experiments is probably due to a downregulation due to the repeated treatment with this tumor promoter agent.
Discussion
PARP-1 is a multifunctional protein and the outcome of its genetical elimination or pharmacological inhibition is dependent on the type and intensity of the stimulus arriving to the cell. In the case of the oxidative cell damage produced during the inflammatory response the initial steps of skin neoplasia, the absence of PARP-1 represents a net advantage because two pathways leading to exacerbating cell and tissue damage, activation of NF-kB and nonapoptotic PARP-1-mediated cell death (Yu et al., 2002) , are avoided through the downregulation/abolition of PARP-1. In the present study, we show that the indirect inhibition of NF-kB by the elimination of PARP-1, result in a dramatic decrease in the incidence of premalignant skin lesions development.
The role of PARP-1 in carcinogenesis and tumor development has been addressed for a long time based on the use of chemical inhibitors and in the last years using parp-1 single-or double-knockout mice after breeding with different DNA surveilling genes (reviewed in Shall and de Murcia, 2000; Conde et al., 2001; Tong et al., 2002) . Although the use of PARP inhibitors to potentiate chemo and radiotherapy has been a longstanding approach from different laboratories in the last decades, all the results reported so far in PARP-1 knockout mice show a tumor type-dependent effect of single parp-1 elimination with respect to carcinogenesis. In this respect, recent reports by Tsutsumi et al. (2001) and Nozaki et al. (2003) indicates that parp-1 knockout mice are more sensitive to chemically induced tumorigenesis in liver and colon, respectively. We think that this controversy is only apparent because the balance between environmental factors (the influence of chronic inflammation and trans-activation of stress-related genes by the tumor and surrounding tissues) and intrinsic components involved in genetic instability of the tumor, is dependent on the type of tumor in study. In our case, the development of skin carcinogenesis the inflammatory status has repeatedly been reported to be key determinant (Moore et al., 1999; Budunova et al., 1999; Bell et al., 2003) .
On the other hand, multiple evidence suggests that activation of NF-kB can lead to tumor cell proliferation, invasion, angiogenesis and metastasis (Gilmore et al., 2002) . Recent work suggests the involvement of p53 promoter activation by NF-kB (Benoit et al., 2000) and the existence of a promoter element that is involved in basal p53 gene expression and the stress response (Noda et al., 2000) . Thus, suppression of NF-kB in cancer cells may provide an additional target for prevention of cancer. NF-kB blockers (which is the case for parp-1 inactivation) can also be considered for the therapy of cancer, perhaps in combination with chemotherapeutic agents or gamma irradiation.
Cancer is a multifactorial disease, and its treatment may also require multimodal therapy. In most instances when the diseases are diagnosed, numerous changes in the tumor have already taken place, thus creating a challenge for the physician to treat the patient. Most recent treatments for cancer have been a combination therapy consisting of chemotherapeutic agents, inhibitors of signal transduction and antibodies against various cell surface antigens. Therefore, it is reasonable to combine chemotherapeutic agents with chemopreventive agents for the treatment of cancer. In this way, our results suggest that targeting PARP-1 might have a clear benefit in tumor treatment by limiting the rate of cell proliferation and activation of NF-kB leading to suppression of inflammation and expression of genes related with tumor progression. Nonetheless, the bene- Interaction between PARP-1 and NF-jB in carcinogenesis D Martín-Oliva et al fits derived from pharmacological inhibition of PARP-1 activity seems not to be related with inhibition of NF-kB activation (Oliver et al., 1999; Hassa et al., 2001) . Thus, new strategies should be conceived in order to locally avoid PARP-1 protein expression such as siRNA, which will have multiple benefits in the short term such as potentiation of chemo-and radiotherapy, inhibition of the inflammatory and tumor promotion-related NF-kB activity and perhaps improving cancer therapy by decreasing the devastating effects of p53 induction in normal tissue and therefore improve the quality of life of patients during treatment.
Materials and methods
Mice/tumor induction protocols
and parp-1 þ / þ mice on the C57BL/6 background were generated by homologous recombination in the de Murcia laboratory, as described previously (de Murcia et al., 1997).
Tumor induction was performed as described before for mice with this genetic background (Moore et al., 1999) . Briefly, mice 6-8 weeks of age were initiated with a single dose of 25 mg DMBA (Sigma, St Louis, MO, USA), applied in 100 ml of acetone to the dorsal surface 2 days after shaving. TPA (12 mg in 200 ml of acetone; Sigma, St Louis, MO, USA), was applied topically twice per week for 25 weeks, beginning 1 week after initiation. Control animals were treated in parallel with acetone alone. The number of tumors more than 1 mm in diameter was counted weekly (Moore et al., 1999; Weinberg et al., 1999) and the experiment was terminated at week 25th when no further tumors were developed (Figure 1a) . A short initiation/promotion protocol was used in order to assess for changes in proliferation, apoptosis and NF-kB activation in the initial steps of carcinogenesis. This treatment consisted of a single dose of DMBA (25 mg) and four doses of 12 mg TPA given over 7 days (Moore et al., 1999) before evaluation of proliferation with BrdU, NF-kB activation, and induction of kB-dependent genes.
Proliferation and apoptosis assays
For proliferation assays, a BrdU pulse labeling was done 24 h after DMBA initiation (25 mg) and four doses of 12 mg TPA given over 7 days. Mice were injected (i.p.) with 200 mg/kg BrdU (Sigma, St Louis, MO, USA) in 0.9% NaCl and were killed after 2 h (Wang et al., 1999) . Biopsied skins were fixed in Carnoy's solution (chloroform-acetic acid-ethanol, 3 : 1 : 6) at 41C overnight, embedded in paraffin and sectioned to 4-mm thickness. For immunofluorescence, samples were stained with monoclonal antibody to BrdU (Sigma, clone BU-33) using standard procedures (Brantley et al., 2001; Greenhalgh et al., 1996) and nuclei were counterstained with propidium iodide (0.5-1 mg/ml). For quantification, random fields per section at Â 400 magnification were documented by confocal microscopy, and the percentage of BrdU-positive epithelial basal cell nuclei relative to the total number of epithelial basal cell nuclei was calculated. Five to eight skin samples were analysed in each animal and random tissue section derived for three animals per genotype were quantified. The total number of epithelial basal cell nuclei (at minimum of 1000) was also quantified in each of these samples. For apoptosis assays, 'in toto' skin biopsies were used in order to optimize visualization of apoptotic cells. Skin biopsies from treated and untreated mice were fixed in 10% (v : v) neutral buffered formalin at 41C overnight and the epidermis was separated after incubating skin biopsy in PBS with 2% Triton X-100 at 41C for 24 h. Fragmented DNA was labeled with ApopTag s Fluorescein In Situ Apoptosis Detection Kit (Intergen) according to the manufacturer's protocol. Aleatory fields per epidermis samples at Â 200 and Â 400 magnification were documented by confocal microscopy. Independent biopsied skins derived for three animals per genotype were visualized.
Electrophoretic mobility shift assay (EMSA)
The double-stranded oligonucleotides 5 0 -TGCTAGGGG-GATTTTCCCTCTTCTTGT-3 0 (Xie et al., 1994) with the Figure 4 Defective NF-kB activation and kB-dependent gene expression in parp-1 À/À mice during tumor promotion. (a) Band shift analysis of NF-kB activation using kB iNOS promoter sequence. Defective NF-kB activation in parp-1-deficient mice epidermis 24 h after skin treatment with one dose of 25 mg DMBA and four aplication of 12 mg TPA, as described in Materials and methods. The results shown is representative of three independent experiments. (b) Expression levels of NF-kB regulated genes in the skin of untreated (C) or treated (T) epidermis of parp-1 À/À mice compared with those of wild-type mice. Poly(A) þ RNA was isolated from the skin of parp-1 À/À and parp-1 þ / þ mice 24 h after treatment with one dose of 25 mg DMBA and four aplication of 12 mg TPA, as described in Materials and methods. Expression levels of genes were determined by semiquantitative RT-PCR. Values are normalized to the level of a-tubulin mRNA and represent mean7s.e.m. of three independent experiments Interaction between PARP-1 and NF-jB in carcinogenesis D Martín-Oliva et al sequences of the binding sites for NF-kB of iNOS promoter were purchased. These oligonucleotides were end-labeled with [g-32 P]ATP and T4 DNA polynucleotide kinase and used as probe. Nuclear extracts of the dorsal skin of untreated or from treated mice with the short protocol described above were obtained according to a previous report (Velasco et al., 1997) . Nuclear extracts (180 ng protein) were incubated with 2 ml of 32 P-labeled probe (6 Â 10 4 d.p.m.) in a final volume of 20 ml of reaction mixture for 15 min at 41C as described previously (Oliver et al., 1999) . The DNA-protein complexes were separated on native 5% polyacrylamide gels in 0.5 Tris-borate EDTA buffer.
Expression of NF-kB-dependent genes DMBA and TPA were applied to the skin of the backs of mice as described above for BrdU labeling and EMSA. Total RNA was isolated from the skin of the mice 24 h after the last TPA treatment by Trizol (Gibco) extraction method, according to the manufacturer's recommendations. Expression of various NF-kB-dependent genes (TNF-a, IL-1b, MnSOD and TRAIL) was determined by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). a-Tubulin was used as an internal control. PCR conditions for amplification of NF-kB-dependent genes were 35 cycles of 951C for 60 s, annealing at 58 or 501C (IL-1b) for 60 s and 721C for 60 s, and a-tubulin annealing at 661C. The results were confirmed by three independent experiments. Primers used were: 5 0 -CCT-GTAGCCCACGTCGTAGC-3 0 (sense) and 5 0 -GTTGAG-TCGCGACTCCAGTT-3 0 (antisense) for TNF-a; 5 0 -AAGG-AGAACCAAGCAACGAC-3 0 (sense) and 5 0 -ACTCGT-CTGTCGAGTTAGAG-3 0 (antisense) for IL-1b; 5 0 -GAC-CTGCCTTACGACTATGG-3 0 (sense) and 5 0 -GACCTT-GCTCCTTATTGAAGC-3 0 (antisense) for MnSOD; 5 0 -TCA-CCAACGAGATGAAGCAGC-3 0 (sense) and 5 0 -CTCA-CCTTGTCCTTTGAGACC-3 0 (antisense) for TRAIL (Musgrave et al., 1999; Liu et al., 2000; Tucker and Sack, 2001) .
Histological techniques
For conventional morphology, three buffered 4% formaldehyde-fixed, paraffin-embedded skin longitudinal tissue sections (all thickness, with or without papillomatous lesion) of parp-1 þ / þ , parp-1 À/À and controls mice in week 25 were stained with hematoxylin and eosin. The study was done in blinded fashion on 4-mm sections with light microscopy. The mitosis and apoptosis cells were assessed by examining their number in 10 high-power field ( Â 600 magnifications) in skin with and without papillomas. A count was made of the number of mastocyte cells in the skin was carried out with a 1 cm 2 grid divided into 100 mm 2 squares, placed in the eyepiece of an Olympus BH2 microscope (10 fields per mouse at Â 400 magnifications were assessed). The results were expressed as number of cells per mm 2 . The presence of papillomas, epithelial hyperplasia, dysplasia, inflammatory infiltrated and pigmentary incontinence were also evaluated.
For morphometric study of epithelium (mean of thickness of epidermis and stratum granulosum) the software for development of image analysis program Visilog s 4.1 (Noesis S.A., Velizy, France) was used and expressed in millimeters.
Statistical analysis
For data shown in Figure 1a and b we have fitted the values of the average number of tumors per mouse and the time after promotion, using the Mann-Whitney u-test. Statistical analysis of other experiments used unpaired Student's t-test ( Figures  2b, c and 3b ).
